Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Endocrinol (Oxf) ; 89(4): 399-407, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-30003563

RESUMO

BACKGROUND: In a phase 2 short-term (6 months) study of patients with congenital adrenal hyperplasia (CAH), continuous subcutaneous hydrocortisone infusion (CSHI) was found to be a safe, effective and well-tolerated method of replacing cortisol with improved disease and patient-related outcomes. OBJECTIVE: To evaluate the safety and efficacy of long-term CSHI. DESIGN: Single-centre, open-label, phase 2 extension study. PATIENTS: Five adults with classic CAH. MEASUREMENTS: Biomarkers of disease control, metabolic indices and health-related quality-of-life (HRQoL) estimates. RESULTS: Six of eight patients chose to continue on long-term CSHI therapy. Compared to baseline, eighteen months of CSHI resulted in decreased (P = 0.043) 0700-hour ACTH, 17-hydroxyprogesterone, androstenedione and progesterone; increased whole-body lean mass (P = 0.024); and improved HRQoL, especially symptoms of adrenal insufficiency (P = 0.003). Findings at six and eighteen months did not differ, and improvements achieved in androgen control, lean body mass and HRQoL after 6 months of CSHI were maintained at eighteen months. The hydrocortisone dose appeared to decrease with time [6 vs 18 months: 38.3 ± 8.8 vs 33.6 ± 12.2 mg/day (P = 0.062)], especially in women receiving oral contraceptives. Reduction of testicular adrenal rest and adrenal size observed at 6 months remained stable. In one patient, an adrenal adenoma continually decreased over time. Subjective improvement in hirsutism was reported. CONCLUSIONS: Long-term use of CSHI is a safe and well-tolerated treatment option in a select set of adults with classic CAH. Improvements observed short term in disease control and subjective health status continued long term.


Assuntos
Hiperplasia Suprarrenal Congênita/tratamento farmacológico , Hidrocortisona/administração & dosagem , Hidrocortisona/uso terapêutico , Hiperplasia Suprarrenal Congênita/sangue , Adulto , Biomarcadores/sangue , Índice de Massa Corporal , Densidade Óssea/efeitos dos fármacos , Feminino , Humanos , Hidrocortisona/efeitos adversos , Hidrocortisona/sangue , Masculino , Espectroscopia de Prótons por Ressonância Magnética , Qualidade de Vida
2.
Am J Surg ; 220(2): 256-261, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32184008

RESUMO

BACKGROUND: A gender pay gap has been reported across many professions, including medicine. METHODS: Surgeons employed at complex Veterans Affairs Medical Centers (VAMC) nationwide in 2016 were identified. Data on salary, gender, years since medical school graduation, professorship status, h-index, and geographic location were collected. RESULTS: Of 1993 surgeons nationwide, 23% were female. On average, female surgeons had significantly lower salaries compared to male surgeons ($268,429 ± 41,339 versus $287,717 ± 45,379, respectively; p < 0.001). Among each surgical specialty, there were no significant differences in salary on univariate analysis. Women were underrepresented in higher paying specialties and more heavily represented in lower paying specialties. On multivariate analysis, gender (p < 0.001), time since medical school graduation (p < 0.001), surgical specialty (p = 0.031), h-index (p < 0.001), and geographic location (p < 0.001) were significant predictors of salary. CONCLUSION: Female gender significantly predicted lower salary among VAMC surgeons, however within each surgical specialty, there was no significant gender pay gap. SENTENCE SUMMARY: Independent predictors of salary included gender, surgical specialty, experience, h-index, and geographic location. Although female surgeons had lower overall salaries compared to male surgeons in the Veterans Health Administration (VHA), there were no significant gender differences in salary among each surgical specialty. Pay transparency, unique to the VHA, along with the use of rational and objective criteria to establish and adjust salaries, may play a role in reducing the gender pay gap among VHA surgeons.


Assuntos
Médicas/economia , Salários e Benefícios/estatística & dados numéricos , Especialidades Cirúrgicas/economia , Cirurgiões/economia , United States Department of Veterans Affairs , Adulto , Feminino , Humanos , Masculino , Área de Atuação Profissional , Fatores Sexuais , Estados Unidos
3.
BMC Res Notes ; 12(1): 711, 2019 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-31666125

RESUMO

OBJECTIVE: Approximately 10% of patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency carry a mutation that disrupts CYP21A2 and the flanking TNXB gene resulting in CAH-X, a contiguous gene deletion syndrome. TNXB encodes tenascin-X (TNX), an extracellular matrix glycoprotein that plays an important role in collagen organization. TNXB impairment is associated with Ehlers-Danlos syndrome. Symptoms include joint hypermobility, hernias and cardiac defects. We measured serum TNX using an antibody targeting the amino-terminal of the TNX protein in 161 subjects, including extensively genotyped and phenotyped CAH patients, their relatives, and healthy controls. RESULTS: We evaluated the potential of serum TNX as a screening tool for CAH-X. CAH-X patients, especially haploinsufficient patients carrying the TNXA-TNXB chimeric gene CAH-X-CH-1 showed reduced TNX levels compared to controls (P < 0.05). TNX levels were similar in all subjects carrying a TNXB mutation. However, CAH patients who did not harbor a TNXB mutation also had reduced TNX compared to controls (P < 0.001). Thus, measuring serum TNX is not an effective screen for CAH-X amongst patients with CAH. TNXB genotyping is recommended for CAH patients who have symptoms of a connective tissue disorder. Epigenetic factors that influence TNX expression require further study.


Assuntos
Hiperplasia Suprarrenal Congênita/sangue , Síndrome de Ehlers-Danlos/sangue , Tenascina/sangue , Tenascina/genética , Adolescente , Hiperplasia Suprarrenal Congênita/genética , Adulto , Idoso , Biomarcadores/sangue , Criança , Pré-Escolar , Doenças do Tecido Conjuntivo/diagnóstico , Síndrome de Ehlers-Danlos/genética , Feminino , Deleção de Genes , Humanos , Instabilidade Articular/diagnóstico , Masculino , Pessoa de Meia-Idade , Mutação , Fenótipo , Esteroide 21-Hidroxilase/genética , Adulto Jovem
4.
J Clin Endocrinol Metab ; 102(8): 2701-2710, 2017 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-28472487

RESUMO

Context: Patients with 21-hydroxylase deficiency (21OHD) have long-term complications, resulting from poor disease control and/or glucocorticoid overtreatment. Lack of optimal biomarkers has made it challenging to tailor therapy and predict long-term outcomes. Objective: To identify biomarkers of disease control and long-term complications in 21OHD. Setting and Participants: Cross-sectional study of 114 patients (70 males), ages 2 to 67 years (median, 15 years), seen in a tertiary referral center. Methods: We correlated a mass-spectrometry panel of 23 steroids, obtained before first morning medication, with bone age advancement (children), adrenal volume (adults), testicular adrenal rest tumors (TART), hirsutism, menstrual disorders, and pituitary hormones. Results: Total adrenal volume correlated positively with 18 steroids, most prominently 21-deoxycortisol and four 11-oxygenated-C19 (11oxC19) steroids: 11ß-hydroxyandrostenedione (11OHA4), 11-ketoandrostenedione (11ketoA4), 11ß-hydroxytestosterone (11OHT), and 11-ketotestosterone (11ketoT) (r ≈ 0.7, P < 0.0001). Nine steroids were significantly higher (P ≤ 0.01) in males with TART compared with those without TART, including 11OHA4 (6.8-fold), 11OHT (4.9-fold), 11ketoT (3.6-fold), 11ketoA4 (3.3-fold), and pregnenolone sulfate (PregS; 4.8-fold). PregS (28.5-fold) and 17-hydroxypregnenolone sulfate (19-fold) levels were higher (P < 0.01) in postpubertal females with menstrual disorders. In males, testosterone levels correlated positively with all 11oxC19 steroids in Tanner stages 1 and 2 (r ≈ 0.7; P < 0.001) but negatively in Tanner stage 5 (r = -0.3 and P < 0.05 for 11ketoA4 and 11ketoT). In females, testosterone level correlated positively with all four 11oxC19 steroids across all Tanner stages (r ≈ 0.8; P < 0.0001). Conclusion: 11oxC19 steroids and PregS might serve as clinically useful biomarkers of disease control and long-term complications in 21OHD.


Assuntos
Hiperplasia Suprarrenal Congênita/metabolismo , Tumor de Resto Suprarrenal/metabolismo , Androgênios/metabolismo , Hirsutismo/metabolismo , Distúrbios Menstruais/metabolismo , Neoplasias Testiculares/metabolismo , 17-alfa-Hidroxipregnenolona/análogos & derivados , 17-alfa-Hidroxipregnenolona/metabolismo , Adolescente , Glândulas Suprarrenais/patologia , Adulto , Determinação da Idade pelo Esqueleto , Idoso , Androstenodiona/análogos & derivados , Androstenodiona/metabolismo , Androstenos/metabolismo , Criança , Pré-Escolar , Cortodoxona/metabolismo , Estudos Transversais , Feminino , Humanos , Hidroxitestosteronas/metabolismo , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Pregnenolona/metabolismo , Testosterona/análogos & derivados , Testosterona/metabolismo , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA